Drug-coated balloons and their place in treating peripheral arterial disease

Expert Review of Medical Devices

Volumn 10, Issue 1, 2013, Pages 105-114

  Schnorr, Beatrix ^a   Albrecht, Thomas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

below the knee; drug coated balloons; paclitaxel; superficial femoral artery

Indexed keywords

ADDITIONAL TREATMENT; BELOW THE KNEE; CLINICAL OUTCOME; LIMITED DATA; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SCIENTIFIC EVIDENCE; SUPERFICIAL FEMORAL ARTERIES;

ORGANIC POLLUTANTS; PATIENT MONITORING; POLYCHLORINATED BIPHENYLS;

BALLOONS;

DRUG CARRIER; IOPROMIDE; N BUTYRYL TRI N HEXYLCITRATE; NITINOL; PACLITAXEL; POLYSORBATE; SHELLAC; SORBITOL; UNCLASSIFIED DRUG; UREA;

ANKLE BRACHIAL INDEX; ARTERY CALCIFICATION; ARTERY DIAMETER; ATHEROSCLEROSIS; BALLOON CATHETER; BARE METAL STENT; CLAUDICATION; CLINICAL EFFECTIVENESS; COMPLICATION; CORONARY STENT; CRITICAL LIMB ISCHEMIA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COATED BALLOON; DRUG COATING; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MANUFACTURE; FOLLOW UP; HUMAN; KNEE; LIMB SALVAGE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NITINOL STENT; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; POPLITEAL ARTERY; RESTENOSIS; REVIEW; STENT FRACTURE; SUPERFICIAL FEMORAL ARTERY; SURVIVAL; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; CATHETERIZATION, PERIPHERAL; DRUG-ELUTING STENTS; EQUIPMENT FAILURE ANALYSIS; HUMANS; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN; TUBULIN MODULATORS;

EID: 84871947601     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.12.67     Document Type: Review

References (57)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1, 263 (1978).
2. Virmani R, Farb A. Pathology of in-stent restenosis. Curr. Opin. Lipidol. 10(6), 499-506 (1999). (Pubitemid 30064019)
3. Axel DI, Kunert W, Göggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96(2), 636-645 (1997). (Pubitemid 27329445)
4. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76(3), 412-417 (1995).
5. Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 119(25), 3198-3206 (2009).
6. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: From preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc. Imaging 2(5), 625-628 (2009).
7. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500-1510 (2007). (Pubitemid 46986103)
8. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110(7), 810-814 (2004). (Pubitemid 39096008)
9. Speck U, Scheller B, Abramjuk C et al. Neointima inhibition: Comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240(2), 411-418 (2006). (Pubitemid 44098636)
10. Scheller B, Hehrlein C, Bocksch W et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin. Res. Cardiol. 97, 773-781 (2008).
11. Scheller B, Clever YP, Kelsch B et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc. Interv. 5(3), 323-330 (2012).
12. Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119(23), 2986-2994 (2009).
13. Unverdorben M, Kleber FX, Heuer H et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin. Res. Cardiol. 99(3), 165-174 (2010).
14. Chen YW, Smith ML, Sheets M et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J. Cardiovasc. Pharmacol. 49(4), 228-235 (2007). (Pubitemid 46626015)
15. Brugaletta S, Burzotta F, Sabaté M. Zotarolimus for the treatment of coronary artery disease: Pathophysiology, DES design, clinical evaluation and future perspective. Expert Opin. Pharmacother. 10(6), 1047-1058 (2009).
16. Wiskirchen J, Schöber W, Schart N et al. The effects of paclitaxel on the three phases of restenosis: Smooth muscle cell proliferation, migration, and matrix formation: An in vitro study. Invest. Radiol. 39(9), 565-571 (2004). (Pubitemid 39096774)
17. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl Acad. Sci. USA 90(20), 9552-9556 (1993). (Pubitemid 23315823)
18. Schnorr B, Kelsch B, Cremers B, Clever YP, Speck U, Scheller B. Paclitaxel-coated balloons Y survey of preclinical data. Minerva Cardioangiol. 58(5), 567-582 (2010).
19. Kelsch B, Scheller B, Biedermann M et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest. Radiol. 46, 255-263 (2011).
20. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation 121(24), 2672-2680 (2010).
21. Speck U, Cremers B, Kelsch B et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ. Cardiovasc. Interv. 5, 392-400 (2012).
22. Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358(7), 689-699 (2008). (Pubitemid 351240748)
23. Werk M, Langner S, Reinkensmeier B et al. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation 118(13), 1358-1365 (2008).
24. Cremers B, Biedermann M, Mahnkopf D, Böhm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin. Res. Cardiol. 98(5), 325-330 (2009).
25. Joner M, Byrne RA, Lapointe JM et al. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb. Haemost. 105(5), 864-872 (2011).
26. Zeller T, Schmitmeier S, Tepe G, Rastan A. Drug-coated balloons in the lower limb. J. Cardiovasc. Surg. (Torino) 52(2), 235-243 (2011).
27. Hirsch AT, Haskal ZJ, Hertzer NR et al.; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113(11), e463-e654 (2006).
28. Schillinger M, Sabeti S, Loewe C et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N. Engl. J. Med. 354(18), 1879-1888 (2006). (Pubitemid 43872689)
29. Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J. Am. Coll. Cardiol. 45(2), 312-315 (2005). (Pubitemid 40094743)
30. Kasapis C, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr. Cardiol. Rev. 5(4), 296-311 (2009).
31. Krankenberg H, Schlüter M, Steinkamp HJ et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation 116(3), 285-292 (2007). (Pubitemid 47196564)
32. Geronemus AR, Peña CS. Endovascular treatment of femoral-popliteal disease. Semin. Intervent. Radiol. 26(4), 303-314 (2009).
33. Dake MD, Ansel GM, Jaff MR et al.; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ. Cardiovasc. Interv. 4(5), 495-504 (2011).
34. Duda SH, Pusich B, Richter G et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation 106(12), 1505-1509 (2002).
35. Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The SIROCCO II trial. J. Vasc. Interv. Radiol. 16(3), 331-338 (2005). (Pubitemid 40354849)
36. Lammer J, Bosiers M, Zeller T et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J. Vasc. Surg. 54(2), 394-401 (2011).
37. Biondi-Zoccai GG, Sangiorgi G, Lotrionte M et al. Infragenicular stent implantation for below-the-knee atherosclerotic disease: Clinical evidence from an international collaborative meta-analysis on 640 patients. J. Endovasc. Ther. 16(3), 251-260 (2009).
38. Siablis D, Karnabatidis D, Katsanos K et al. Infrapopliteal application of sirolimuseluting versus bare metal stents for critical limb ischemia: Analysis of long-term angiographic and clinical outcome. J. Vasc. Interv. Radiol. 20(9), 1141-1150 (2009).
39. Dosluoglu H, Lall P. Infrainguinal disease treatment: To stent or not to stent. J. Cardiovasc. Surg. (Torino) 52(5), 701-716 (2011).
40. Bosiers M, Deloose K, Callaert J, Keirse K, Verbist J, Peeters P. Drug-eluting stents below the knee. J. Cardiovasc. Surg. (Torino) 52(2), 231-234 (2011).
41. Albrecht T, Speck U, Baier C, Wolf KJ, Böhm M, Scheller B. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest. Radiol. 42(8), 579-585 (2007). (Pubitemid 47051835)
42. Freyhardt P, Zeller T, Kröncke TJ et al. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries. Rofo 183, 448-455 (2011).
43. Tepe G, Zeller T, Albrecht T et al. Long-term clinical data of Paccocath technology and future clinical designs. presented at: Leipzig Interventional Course (LINC). Leipzig, Germany, 25-28 January 2012.
44. Scheinert D. 6-month results of the LEVANT I-Trial. Presented at: Transcatheter Cardiovascular Therapeutics (TCT). Washington, DC, USA, 21-25 September 2010.
45. Werk M, Albrecht T, Meyer DR et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: Evidence from the randomized PACIFIER trial. Circ. Cardiovasc. Interv. doi: 0.1161/circinterventions.112. 971630 (2012) (Epub ahead of print).
46. Micari A, Cioppa A, Vadalà G et al. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: Acute and midterm results. EuroIntervention 7(Suppl. K), K77-K82 (2011).
47. Cassese S, Byrne RA, Ott I et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: A meta-analysis of randomized trials. Circ. Cardiovasc. Interv. 5, 582-529 (2012).
48. Zeller T, Rastan A, Schwarzwälder U et al. Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device. J. Vasc. Interv. Radiol. 15(12), 1391-1397 (2004). (Pubitemid 39628509)
49. Sixt S, Rastan A, Beschorner U et al. Acute and long-term outcome of Silverhawk assisted atherectomy for femoro-popliteal lesions according the TASC II classification: A single-center experience. VASA 39(3), 229-236 (2010).
50. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J. Vasc. Surg. 47(5), 975-981 (2008).
51. Siablis D, Karnabatidis D, Katsanos K et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: Enduring 1-year angiographic and clinical benefit. J. Endovasc. Ther. 14(2), 241-250 (2007). (Pubitemid 46776123)
52. Rastan A, Tepe G, Krankenberg H et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: A double-blind, multi-centre, randomized clinical trial. Eur. Heart J. 32(18), 2274-2281 (2011).
53. Diehm NA, Hoppe H, Do DD. Drug eluting balloons. Tech. Vasc. Interv. Radiol. 13(1), 59-63 (2010).
54. Fanelli F, Cannavale A, Boatta E et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J. Endovasc. Ther. (19), 571-580 (2012).
55. Schmidt A, Piorkowski M, Werner M et al. First experience with drug-eluting balloons in infrapopliteal arteries: Restenosis rate and clinical outcome. J. Am. Coll. Cardiol. 58(11), 1105-1109 (2011).
56. Schmidt A, Ulrich M, Winkler B et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter. Cardiovasc. Interv. 76(7), 1047-1054 (2010).
57. Cortese B, Micheli A, Picchi A et al. Paclitaxel-coated balloon versus drugeluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 96(16), 1291-1296 (2010).